Rafael Guimarães Dos Santos (Rafael G Dos Santos)

ResearcherID Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 29

Top Topics

Major Depressive Disorder

Randomized Controlled Trial

Systematic Review

Prefrontal Cortex

Top Venues

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)

European archives of psychiatry and clinical neuroscience

British journal of pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Isabel Werle, Laura M M Nascimento, Aymee L A Dos Santos, Luciane A Soares, Rafael Guimarães Dos Santos, Jaime Eduardo Cecílio Hallak, Leandro J Bertoglio
Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT 2A and 5-HT 1A receptors. British journal of pharmacology (2024)
Rafael Guimarães Dos Santos, Isabella C da Silva Dias, Antonio W Zuardi, Regina H C Queiroz, Francisco S Guimarães, Jaime E C Hallak, José Alexandre S Crippa
Lack of Acute Agomelatine Effect in a Model of Social Anxiety in Healthy Volunteers: A Double-Blind, Placebo-Controlled Trial. Journal of clinical psychopharmacology (2024)
Isabel Werle, Laura M M Nascimento, Aymee L A Dos Santos, Luciane A Soares, Rafael Guimarães Dos Santos, Jaime Eduardo Cecílio Hallak, Leandro J Bertoglio
Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT 2A and 5-HT 1A receptors. British journal of pharmacology 181 (11) (2024)
Arilton Martins Fonseca, Rafael Guimarães Dos Santos, Lívia Soman de Medeiros, Thiago André Moura Veiga, Fernando Cassas, Carla Poleselli Bruniera, Giordano Novak Rossi, José Carlos Bouso, Jaime E Cecílio Hallak, Fabiana Pereira Santos, Beatriz Aparecida Passos Bismara Paranhos, Mauricio Yonamine, Eliana Rodrigues
Long-term ayahuasca use is associated with preserved global cognitive function and improved memory: a cross-sectional study with ritual users. European archives of psychiatry and clinical neuroscience (2024)
Isabel Werle, Laura M M Nascimento, Aymee L A Dos Santos, Luciane A Soares, Rafael Guimarães Dos Santos, Jaime Eduardo Cecílio Hallak, Leandro J Bertoglio
Ayahuasca-enhanced extinction of fear behaviour: Role of infralimbic cortex 5-HT 2A and 5-HT 1A receptors. British journal of pharmacology 181 (11) (2024)
Genís Ona, Ingrid Reverte, Giordano Novak Rossi, Rafael Guimarães Dos Santos, Jaime Ec Hallak, Maria Teresa Colomina, José Carlos Bouso Saiz
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview. Journal of psychopharmacology (Oxford, England) (2023)
Juliana Mendes Rocha, José A S Reis, José Carlos Bouso, Jaime E C Hallak, Rafael Guimarães Dos Santos
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies. European archives of psychiatry and clinical neuroscience (2023)
José Diogo R Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno O de-Paulo, Antonio W Zuardi, Francisco S Guimarães, Jaime E C Hallak, José Alexandre de Souza Crippa, Rafael Guimarães Dos Santos
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14 (12) (2022)
José Diogo R Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno O de-Paulo, Antonio W Zuardi, Francisco S Guimarães, Jaime E C Hallak, José Alexandre de Souza Crippa, Rafael Guimarães Dos Santos
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14 (12) (2022)
José Diogo R Souza, Julia Cozar Pacheco, Giordano Novak Rossi, Bruno O de-Paulo, Antonio W Zuardi, Francisco S Guimarães, Jaime E C Hallak, José Alexandre de Souza Crippa, Rafael Guimarães Dos Santos
Adverse Effects of Oral Cannabidiol: An Updated Systematic Review of Randomized Controlled Trials (2020-2022). Pharmaceutics 14 (12) (2022)
Giordano Novak Rossi, Isabella Caroline da Silva Dias, Glen Baker, José Carlos Bouso Saiz, Serdar M Dursun, Jaime E C Hallak, Rafael Guimarães Dos Santos
Ayahuasca, a potentially rapid acting antidepressant: focus on safety and tolerability. Expert opinion on drug safety 21 (6) (2022)
Maja Kohek, Genís Ona, Michiel van Elk, Rafael Guimarães Dos Santos, Jaime E C Hallak, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso Saiz
Ayahuasca and Public Health II: Health Status in a Large Sample of Ayahuasca-Ceremony Participants in the Netherlands. Journal of psychoactive drugs (2022)
Rafael Guimarães Dos Santos, Juliana Mendes Rocha, Giordano Novak Rossi, Flávia L Osório, Genís Ona, José Carlos Bouso Saiz, Gabriela de Oliveira Silveira, Mauricio Yonamine, Camila Marchioni, Eduardo José Crevelin, Maria Eugênia Queiroz, José Alexandre Crippa, Jaime E C Hallak
Effects of ayahuasca on the endocannabinoid system of healthy volunteers and in volunteers with social anxiety disorder: Results from two pilot, proof-of-concept, randomized, placebo-controlled trials. Human psychopharmacology 37 (4) (2022)
Giordano Novak Rossi, Jaime E C Hallak, Glen Baker, Serdar M Dursun, Rafael Guimarães Dos Santos
The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials. European archives of psychiatry and clinical neuroscience (2022)
Giordano Novak Rossi, Lorena T L Guerra, Glen B Baker, Serdar M Dursun, José Carlos Bouso Saiz, Jaime E C Hallak, Rafael Guimarães Dos Santos
Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules 12 (11) (2022)
Giordano Novak Rossi, Jaime E C Hallak, José Carlos Bouso Saiz, Rafael Guimarães Dos Santos
Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges. Expert opinion on drug safety 21 (6) (2022)
Lucas Silva Rodrigues, Giordano Novak Rossi, Juliana Mendes Rocha, Flávia L Osório, José Carlos Bouso, Jaime E Cecílio Hallak, Rafael Guimarães Dos Santos
Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies. European archives of psychiatry and clinical neuroscience (2021)
Rafael Guimarães Dos Santos, Jaime Ec Hallak, Glen Baker, Serdar Dursun
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Journal of psychopharmacology (Oxford, England) 35 (4) (2021)
Rafael Guimarães Dos Santos, José Carlos Bouso Saiz, Jaime Eduardo Cecílio Hallak
Hallucinogens/psychedelics resurrected as new tools in psychiatric therapy. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 43 (2) (2021)
Ícaro Durante, Rafael Guimarães Dos Santos, José Carlos Bouso Saiz, Jaime Eduardo Cecílio Hallak
Risk assessment of ayahuasca use in a religious context: self-reported risk factors and adverse effects. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 43 (4) (2021)
Rafael Guimarães Dos Santos, José Carlos Bouso, Juliana Mendes Rocha, Giordano Novak Rossi, Jaime E Hallak
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk management and healthcare policy 14 (2021)
Rafael Guimarães Dos Santos, Draulio B de Araujo, Rafael F Sanches, Jaime Eduardo Cecílio Hallak
Unveiling ayahuasca psychopharmacology: the accomplishments of Jordi Riba (1968-2020). Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) (2020)
Rafael Guimarães Dos Santos, Flavia de Lima Osório, Rocío Martín-Santos, Antonio Waldo Zuardi, Jaime Eduardo Cecílio Hallak, José Alexandre de Souza Crippa
Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. CNS drugs 33 (10) (2020)
Rafael Guimarães Dos Santos, Francisco S Guimarães, José Alexandre S Crippa, Jaime E C Hallak, Giordano Novak Rossi, Juliana Mendes Rocha, Antônio W Zuardi
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert opinion on drug metabolism & toxicology 16 (6) (2020)
Genís Ona, Maja Kohek, Tomàs Massaguer, Alfred Gomariz, Daniel F Jiménez, Rafael Guimarães Dos Santos, Jaime E C Hallak, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso Saiz
Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. Journal of psychoactive drugs 51 (2) (2019)
Rafael Guimarães Dos Santos, José Carlos Bouso, Jaime E C Hallak
Serotonergic hallucinogens/psychedelics could be promising treatments for depressive and anxiety disorders in end-stage cancer. BMC psychiatry 19 (1) (2019)
Juliana M Rocha, Flávia L Osório, José Alexandre S Crippa, José Carlos Bouso, Giordano N Rossi, Jaime E C Hallak, Rafael Guimarães Dos Santos
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. Therapeutic advances in psychopharmacology 9 (2019)
Rafael Guimarães Dos Santos, José Carlos Bouso
Translational evidence for ayahuasca as an antidepressant: what's next? Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 41 (4) (2019)
Rafael Guimarães Dos Santos, José Carlos Bouso, Miguel Ángel Alcázar-Córcoles, Jaime E C Hallak
Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Expert review of clinical pharmacology 11 (9) (2018)